{
  "schema": "hangingcontext.desk/1",
  "type": "story",
  "id": "1309",
  "slug": "biotech-q3-cash-runways",
  "edition": "2026-11-09T12",
  "url": "https://hangingcontext.com/stories/2026-11-09/biotech-q3-cash-runways/",
  "newsroom": "finance-investing",
  "beat": null,
  "newsroom_title": "Finance & Investing",
  "angle": "Small biotechs used Q3 to show how long their cash lasts while pipeline readouts decide their fate.",
  "headline": "Small Biotechs Show Their Cash Runways as Pipeline Readouts Loom",
  "dek": "Praxis holds about $1.3 billion into 2028 with two FDA decisions ahead. Editas runs into late 2028, Turn into late 2027, and Abeona is already selling a gene therapy.",
  "published_at": "2026-11-09T12:40:47Z",
  "labels": {
    "trust": "confirmed",
    "trust_text": "Confirmed · 4 Manifests",
    "newsroom": "Finance & Investing"
  },
  "source_count": 4,
  "publishers": [
    "sec-company-0000318306",
    "sec-company-0001650664",
    "sec-company-0001689548",
    "sec-company-0002023016"
  ],
  "sources": [
    "sec-company-0000318306",
    "sec-company-0001650664",
    "sec-company-0001689548",
    "sec-company-0002023016"
  ],
  "distinct_source_count": 4,
  "key_facts": [
    {
      "text": "Praxis Precision Medicines reported cash and investments of about $1.3 billion at September 30, 2026, enough to fund operations into 2028, with a net loss of $94.2 million in the quarter; the FDA target action dates are December 27, 2026, for relutrigine and January 29, 2027, for ulixacaltamide.",
      "cites": [
        {
          "claim_ids": [
            "1794226156100162292",
            "1794226156118162295",
            "1794226156104162293",
            "1794226156111162294"
          ],
          "manifest_id": "1794225851147161245"
        }
      ],
      "self_reported": true
    },
    {
      "text": "Editas Medicine reported cash, cash equivalents and marketable securities of $190.2 million at September 30, 2026, expected to fund operations into the second half of 2028, with a net loss of $23.4 million; it won approval to start the Phase 1/2 Strive study of EDIT-401 in Australia.",
      "cites": [
        {
          "claim_ids": [
            "1794226174211163238",
            "1794226174213163239",
            "1794226174217163242",
            "1794226174209163237"
          ],
          "manifest_id": "1794225982497161591"
        }
      ],
      "self_reported": true
    },
    {
      "text": "Turn Therapeutics expects its cash to fund operations into the third quarter of 2027; in the GX-03 Stage 1 trial, 59.3 percent of patients achieved clear or almost clear skin after four weeks, against 30.4 percent on vehicle, and 40.7 percent achieved EASI-100 at Week 8, against 17.4 percent on vehicle.",
      "cites": [
        {
          "claim_ids": [
            "1794226170100162933",
            "1794226170094162929",
            "1794226170096162930",
            "1794226170097162931"
          ],
          "manifest_id": "1794225878433161359"
        }
      ],
      "self_reported": true
    },
    {
      "text": "Abeona Therapeutics reported third-quarter net ZEVASKYN revenue of $13.5 million, acquired the Phase 3-ready asset APT-1011 from Ellodi Pharmaceuticals for $20 million in common stock, agreed a $30 million private placement financing, and held $134.9 million in cash, cash equivalents and short-term investments at September 30, 2026, with a net loss of $4.8 million.",
      "cites": [
        {
          "claim_ids": [
            "1794224439561155144",
            "1794224439563155145",
            "1794224439565155146",
            "1794224439569155149",
            "1794224439567155148"
          ],
          "manifest_id": "1794224258689154416"
        }
      ],
      "self_reported": true
    }
  ],
  "images": [],
  "sections": [
    {
      "heading": "Praxis: the longest runway, the nearest decisions",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794226156100162292",
                "1794226156118162295",
                "1794226156104162293",
                "1794226156111162294",
                "1794226156131162297",
                "1794226156143162298"
              ],
              "manifest_id": "1794225851147161245"
            }
          ],
          "markdown": "Praxis Precision Medicines reported cash and investments of about $1.3 billion at September 30, 2026, the filing says, enough to maintain its runway into 2028. The company incurred a net loss of $94.2 million for the third quarter, with research and development expenses of $64.2 million and general and administrative expenses of $42.7 million. Two FDA reviews are now the deciding events: relutrigine, with a target action date of December 27, 2026, and ulixacaltamide, with a target action date of January 29, 2027."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794226156187162300",
                "1794226156125162296",
                "1794226156118162295",
                "1794226156191162301"
              ],
              "manifest_id": "1794225851147161245"
            }
          ],
          "markdown": "Topline results from the EMERALD study of relutrigine in broad developmental and epileptic encephalopathies are expected in the fourth quarter of 2026, the filing says, and Praxis expects to host an Investor Day on November 12, 2026. In July 2026 the company started a strategic collaboration with Remagine Labs to develop a transdermal patch of ulixacaltamide. Praxis had 27.9 million shares of common stock outstanding at September 30, 2026."
        }
      ]
    },
    {
      "heading": "Editas: gene editing with time to run",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794226174211163238",
                "1794226174213163239",
                "1794226174217163242",
                "1794226174216163241",
                "1794226174219163243",
                "1794226174220163244",
                "1794226174221163245"
              ],
              "manifest_id": "1794225982497161591"
            }
          ],
          "markdown": "Editas Medicine reported cash, cash equivalents and marketable securities of $190.2 million at September 30, 2026, the filing says, and expects that cash to fund operating expenses and capital spending into the second half of 2028. The company reported a net loss of $23.4 million for the quarter. Collaboration and other research and development revenues rose to $10.4 million from $7.5 million a year earlier, while research and development expenses rose to $21.2 million from $19.8 million and general and administrative expenses to $13.5 million from $12.3 million."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794226174209163237",
                "1794226174223163246",
                "1794226174214163240",
                "1794226174216163241"
              ],
              "manifest_id": "1794225982497161591"
            }
          ],
          "markdown": "Editas received Human Research Ethics Committee approval in Australia and completed the Clinical Trial Notification process with Australia's Therapeutic Goods Administration to start the Phase 1/2 Strive study of EDIT-401. Preclinical data showed LDL cholesterol reduction of at least 90 percent maintained over 10 months in an ongoing study in non-human primates. A second IND/CTA was accepted for the CD70 HD Allo CAR T program under the collaboration with Bristol Myers Squibb, triggering a milestone payment to Editas; the filing does not disclose the amount. Dan Ory was appointed chief medical officer in September 2026."
        }
      ]
    },
    {
      "heading": "Turn: data first, cash second",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794226170100162933",
                "1794226170094162929",
                "1794226170096162930",
                "1794226170097162931",
                "1794226170106162937",
                "1794226170107162938"
              ],
              "manifest_id": "1794225878433161359"
            }
          ],
          "markdown": "Turn Therapeutics expects its cash to fund operations into the third quarter of 2027, the filing says, though it does not disclose the cash balance. The evidence it offered instead was clinical: in the Stage 1 trial of GX-03 for atopic dermatitis, 59.3 percent of patients achieved clear or almost clear skin after four weeks, compared with 30.4 percent receiving vehicle, and 40.7 percent achieved EASI-100 at Week 8, compared with 17.4 percent on vehicle. The ongoing Phase 2b trial is evaluating GX-03 in 120 to 136 atopic dermatitis patients and has recorded no patient dropouts to date."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794226170099162932",
                "1794226170103162935",
                "1794226170102162934",
                "1794226170105162936"
              ],
              "manifest_id": "1794225878433161359"
            }
          ],
          "markdown": "Robert R. Redfield was appointed chief scientific officer effective September 9, 2026. Turn expects to report topline results from the Phase 2b atopic dermatitis trial in the first quarter of 2027, and enrollment for the hidradenitis suppurativa trial is expected to begin in the first quarter of 2027. In animal studies, GX-03 reduced IL-36 by about 50 percent and IL-31 by nearly 68 percent."
        }
      ]
    },
    {
      "heading": "Abeona: already selling",
      "paragraphs": [
        {
          "cites": [
            {
              "claim_ids": [
                "1794224439561155144",
                "1794224439567155148",
                "1794224439569155149",
                "1794224439574155153",
                "1794224439572155151"
              ],
              "manifest_id": "1794224258689154416"
            }
          ],
          "markdown": "Abeona Therapeutics is the one company in this group already selling a product. Net ZEVASKYN revenue for the quarter ended September 30, 2026, was $13.5 million, the filing says. The net loss was $4.8 million, or $0.08 per share. Cash, cash equivalents and short-term investments totaled $134.9 million at September 30, 2026. Revenue was not recognized for one treatment in the quarter because the batch did not meet the release criterion for the identity assay. Abeona expanded its ZEVASKYN QTC network to eight sites during the quarter."
        },
        {
          "cites": [
            {
              "claim_ids": [
                "1794224439563155145",
                "1794224439565155146",
                "1794224439570155150",
                "1794224439566155147",
                "1794224439573155152"
              ],
              "manifest_id": "1794224258689154416"
            }
          ],
          "markdown": "Abeona also announced the acquisition of the Phase 3-ready asset APT-1011, now ABO-801, from Ellodi Pharmaceuticals for $20 million in common stock, with Ellodi eligible for up to $60 million in milestone payments and tiered royalties, and a $30 million private placement financing. ZEVASKYN New Technology Add-on Payment status became effective October 1, 2026, to support hospital reimbursement. Abeona is also eligible for commercial milestone payments and royalties of up to 8 percent on FAYUVI sales from Ultragenyx."
        }
      ]
    }
  ],
  "unresolved": [
    "The dollar amount of the milestone payment Editas received from Bristol Myers Squibb",
    "Final FDA approval decisions for relutrigine and ulixacaltamide",
    "The final regulatory approval timeline for ABO-801",
    "The specific timing for the use of Abeona's private placement financing proceeds",
    "Turn Therapeutics' cash balance, which the filing states only as a runway into the third quarter of 2027"
  ],
  "decision_card": {
    "not_for": [
      "Investment advice",
      "A prediction of FDA approval decisions or trial outcomes"
    ],
    "useful_for": [
      "Investors tracking small biotech cash runways",
      "Readers following gene-editing and CNS drug pipelines",
      "Anyone watching commercial-stage transitions in biotech"
    ],
    "compare_against": [
      "Each company's prior-quarter cash position",
      "The PDUFA dates for relutrigine and ulixacaltamide",
      "Earlier clinical data for GX-03 and EDIT-401"
    ]
  },
  "writer": {
    "agent": "muse",
    "run_id": "2026-11-09T12"
  },
  "corrections": [],
  "cited_manifest_ids": [
    "1794225851147161245",
    "1794225982497161591",
    "1794225878433161359",
    "1794224258689154416"
  ],
  "manifests": [
    {
      "title": "8-K - Current report",
      "source_url": "https://sec.gov/Archives/edgar/data/1689548/000168954826000086/praxisq32026pr.htm",
      "manifest_id": "1794225851147161245",
      "source_name": "sec-company-0001689548",
      "published_date": "2026-11-09"
    },
    {
      "title": "8-K - Current report",
      "source_url": "https://sec.gov/Archives/edgar/data/1650664/000165066426000100/editasmedicinepressrelease.htm",
      "manifest_id": "1794225982497161591",
      "source_name": "sec-company-0001650664",
      "published_date": "2026-11-09"
    },
    {
      "title": "8-K - Current report",
      "source_url": "https://sec.gov/Archives/edgar/data/2023016/000121390026117180/ea031139901ex99-1.htm",
      "manifest_id": "1794225878433161359",
      "source_name": "sec-company-0002023016",
      "published_date": "2026-11-09"
    },
    {
      "title": "8-K - Current report",
      "source_url": "https://sec.gov/Archives/edgar/data/318306/000149315226050609/ex99-1.htm",
      "manifest_id": "1794224258689154416",
      "source_name": "sec-company-0000318306",
      "published_date": "2026-11-09"
    }
  ],
  "run_these_manifests": {
    "title": "Run these Manifests yourself",
    "summary": "Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.",
    "manifest_ids": [
      "1794225851147161245",
      "1794225982497161591",
      "1794225878433161359",
      "1794224258689154416"
    ],
    "steps": [
      {
        "n": 1,
        "title": "Get a Synorb Key",
        "text": "Click Generate Free Agent Key at https://synorb.com/connect/start, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{\"client\":\"your-agent-name\"}`. The key is the `api_key` field of the answer. Save the key. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons."
      },
      {
        "n": 2,
        "title": "Read each cited Manifest by id",
        "text": "REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief."
      },
      {
        "n": 3,
        "title": "Check the claim",
        "text": "Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them."
      }
    ],
    "mcp_url": "https://mcp.synorb.com/mcp",
    "connect_url": "https://synorb.com/connect/start",
    "request": {
      "method": "GET",
      "url_template": "https://api.synorb.com/manifests/by-id/{manifest_id}",
      "headers": {
        "Authorization": "Bearer <SYNORB_KEY>"
      }
    },
    "commands": {
      "one": "curl -s -H \"Authorization: Bearer $SYNORB_KEY\" https://api.synorb.com/manifests/by-id/1794225851147161245",
      "all": "for id in 1794225851147161245 1794225982497161591 1794225878433161359 1794224258689154416; do\n  curl -s -H \"Authorization: Bearer $SYNORB_KEY\" \"https://api.synorb.com/manifests/by-id/$id\"\ndone"
    }
  },
  "links": {
    "html": "https://hangingcontext.com/stories/2026-11-09/biotech-q3-cash-runways/",
    "json": "https://hangingcontext.com/stories/2026-11-09/biotech-q3-cash-runways/index.json",
    "markdown": "https://hangingcontext.com/stories/2026-11-09/biotech-q3-cash-runways/index.md",
    "newsroom": "https://hangingcontext.com/n/finance-investing/",
    "edition": "https://hangingcontext.com/editions/2026-11-09T12/"
  },
  "related": [
    {
      "url": "https://hangingcontext.com/stories/2026-11-11/trump-accounts-explained/",
      "headline": "Trump Accounts, explained: the $5,000 limit, the IRA structure, and the 529 question",
      "slug": "trump-accounts-explained"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-11/hiring-again-still-squeezed/",
      "headline": "Hiring again, still squeezed: the pay cheque grew and the bills grew faster",
      "slug": "hiring-again-still-squeezed"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-10/restatements-rewrite-the-quarter/",
      "headline": "Two restatements, two guidance cuts, and a raise that came with a correction",
      "slug": "restatements-rewrite-the-quarter"
    },
    {
      "url": "https://hangingcontext.com/stories/2026-11-10/energy-contracts-turning-to-cash/",
      "headline": "Energy deals are turning into operating plants, signed power, and raised guidance",
      "slug": "energy-contracts-turning-to-cash"
    }
  ],
  "sponsor": {
    "label": "From Synorb",
    "title": "Ask what Synorb covers",
    "text": "The MCP tool synorb-stream-search answers questions like \"do you have this publisher?\" without using any Manifest allowance.",
    "cta": {
      "label": "Connect and ask",
      "url": "https://synorb.com/connect/start"
    },
    "note": "House ad for Synorb, the publisher of the data behind this paper. Not a news item."
  },
  "disclosure": "Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.",
  "reuse": {
    "version": "1",
    "summary": "Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product.",
    "attribution": "Hanging Context, with provenance by Synorb",
    "link_rule": "Link to the story's canonical URL (the url field of the story).",
    "keep_ids_rule": "When you republish a claim, keep the Manifest ids that the story cites for it.",
    "no_endorsement": "Do not imply that Synorb or Hanging Context endorses you, your product or your use.",
    "license_url": "https://hangingcontext.com/terms/reuse/",
    "machine_url": "https://hangingcontext.com/.well-known/reuse.json",
    "canonical_url": "https://hangingcontext.com/stories/2026-11-09/biotech-q3-cash-runways/"
  }
}